Abbott Park, Illinois, United States; Sydney, Australia, November 19, 2026
Abbott has initiated the VOYAGER CE clinical trial to evaluate the safety and efficacy of its investigational Encantor™ software-guided balloon-expandable transcatheter aortic valve implantation (TAVI) system for treating patients with symptomatic severe aortic stenosis. The announcement marks a significant advancement in Abbott’s structural heart technology development, as the company seeks to expand treatment options for patients affected by severe narrowing of the aortic valve. The first patient enrolment in the VOYAGER CE study took place at Macquarie University in Sydney, Australia, under the leadership of Stephen Worthley, M.B.B.S., Ph.D. The prospective, single-arm, pre-market clinical investigation is expected to enrol up to 300 patients across Europe and Australia who have symptomatic severe aortic stenosis caused by significant calcium accumulation in the aortic valve. The study is intended to generate clinical evidence supporting future regulatory submissions in these markets. Encantor incorporates a differentiated balloon-expandable design with software-guided deployment technology intended to optimise valve expansion according to each patient’s individual anatomy. Through this approach, Abbott aims to support more controlled implantation, procedural precision and consistent valve performance.
VOYAGER CE Trial Evaluates Safety and Efficacy
The VOYAGER CE study will assess the safety and performance of the investigational Encantor TAVI system in patients with symptomatic severe aortic stenosis. The trial will collect clinical information to evaluate how the device performs during and after implantation, including relevant safety, functional and haemodynamic outcomes. Aortic stenosis is a progressive heart valve condition in which calcium deposits cause the aortic valve to become narrowed and stiff. As the opening becomes smaller, blood flow from the left ventricle into the aorta is restricted, forcing the heart to work harder to pump oxygen-rich blood throughout the body. Patients may experience chest pain, breathlessness, fatigue and fainting, while untreated severe disease can lead to heart failure and other life-threatening complications. Transcatheter aortic valve implantation provides an alternative to traditional open-heart valve replacement for appropriately selected patients. By delivering a replacement valve through a catheter, TAVI can avoid the need for conventional open surgical access to the heart. The VOYAGER CE trial will investigate whether Encantor’s software-guided deployment approach can provide a controlled and anatomically tailored valve implantation option. Successful completion of the study, together with the required regulatory review, will be necessary before the system can become commercially available.
Software-Guided Balloon Expansion Supports Precise Implantation
A key differentiating feature of Encantor is its software-guided balloon-expandable technology. The system works by mounting a replacement heart valve onto a deflated surgical balloon, which is then introduced into the body through a catheter inserted into an artery in the groin. The catheter is guided towards the heart until the replacement valve reaches the position of the diseased aortic valve. Once correctly positioned, software-guided deployment helps customise the expansion of the balloon-mounted valve to the patient’s unique anatomy. The replacement valve then takes over the function of the damaged native valve, helping restore blood flow through the aortic opening. Following deployment, the balloon is deflated and withdrawn from the body. Abbott designed the system to support controlled valve expansion, procedural ease of use and favourable haemodynamic performance. The technology draws on physician feedback, engineering developments and experience gained through the company’s existing Navitor™ TAVI portfolio. While both systems deliver replacement valves through a catheter, they use different expansion mechanisms: Encantor uses balloon expansion guided by software, whereas Navitor uses a self-expanding valve. If approved, Encantor would complement Abbott’s existing structural heart technologies by offering physicians another valve platform to consider for individual patient requirements.
Early Feasibility Findings Support Further Clinical Development
The initiation of VOYAGER CE follows findings from an earlier Encantor early feasibility study, which supported progression into the larger pre-market clinical investigation. Abbott plans to present six-month safety, haemodynamic and functional outcome data from the early feasibility study during an innovation session at PCR London Valves 2026, scheduled for November 22–24, 2026. The presentation is expected to provide additional insight into the system’s clinical performance and its potential role in transcatheter heart valve procedures. Abbott also plans to initiate a pivotal clinical trial in the United States in the coming months. The company stated that the investigational Encantor system is designed to broaden its structural heart portfolio and provide physicians with additional technology options for treating aortic valve disease. However, Encantor remains investigational and is not approved for commercial use anywhere in the world, including the United States, Australia, Canada and Europe. Further clinical evaluation and applicable regulatory authorisations will be required before it can be used commercially. The VOYAGER CE programme represents an important step in Abbott’s efforts to advance next-generation TAVI technology and expand innovation in minimally invasive cardiovascular treatment.
Source: Abbott press release



